CA2914669C - Procede de preparation de mesylate d'imatinib cristallin - Google Patents

Procede de preparation de mesylate d'imatinib cristallin Download PDF

Info

Publication number
CA2914669C
CA2914669C CA2914669A CA2914669A CA2914669C CA 2914669 C CA2914669 C CA 2914669C CA 2914669 A CA2914669 A CA 2914669A CA 2914669 A CA2914669 A CA 2914669A CA 2914669 C CA2914669 C CA 2914669C
Authority
CA
Canada
Prior art keywords
imatinib mesylate
needle shaped
crystalline
shaped form
reaction mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2914669A
Other languages
English (en)
Other versions
CA2914669A1 (fr
Inventor
Bhagat Raj PIPAL
Mr. VEERESHAPPA
Manish Sharma
Akshay Kant CHATURVEDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shilpa Medicare Ltd
Original Assignee
Shilpa Medicare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shilpa Medicare Ltd filed Critical Shilpa Medicare Ltd
Publication of CA2914669A1 publication Critical patent/CA2914669A1/fr
Application granted granted Critical
Publication of CA2914669C publication Critical patent/CA2914669C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2914669A 2013-06-12 2014-04-04 Procede de preparation de mesylate d'imatinib cristallin Expired - Fee Related CA2914669C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2548CH2013 2013-06-12
IN2548/CHE/2013 2013-06-12
PCT/IB2014/060430 WO2014199244A2 (fr) 2013-06-12 2014-04-04 Procédé de préparation de mésylate d'imatinib cristallin

Publications (2)

Publication Number Publication Date
CA2914669A1 CA2914669A1 (fr) 2014-12-18
CA2914669C true CA2914669C (fr) 2017-05-09

Family

ID=52022852

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2914669A Expired - Fee Related CA2914669C (fr) 2013-06-12 2014-04-04 Procede de preparation de mesylate d'imatinib cristallin

Country Status (5)

Country Link
US (1) US20160122315A1 (fr)
EP (1) EP3007699A4 (fr)
AU (1) AU2014279765A1 (fr)
CA (1) CA2914669C (fr)
WO (1) WO2014199244A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160143850A1 (en) * 2013-07-09 2016-05-26 Shilpa Medicare Limited Oral Pharmaceutical Compositions Comprising Imatinib Mesylate
WO2015188243A1 (fr) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda Procédé de préparation d'imatinib et de mésylate d'imatinib sous forme α2 non aciculaire
US20190282500A1 (en) * 2016-09-09 2019-09-19 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6940320B2 (en) * 2003-10-14 2005-09-06 Semiconductor Components Industries, L.L.C. Power control system startup method and circuit
PL1720853T3 (pl) * 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
WO2006024863A1 (fr) * 2004-09-02 2006-03-09 Cipla Limited Forme cristalline stable d'imatinib mesylate et son procede de preparation
WO2006048890A1 (fr) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Forme cristalline d'imatinib mesylate et procede d'elaboration
WO2006054314A1 (fr) * 2004-11-17 2006-05-26 Natco Pharma Limited Formes polymorphes de mesylate d'imatinibe
EP2311821A1 (fr) * 2006-04-27 2011-04-20 Sicor, Inc. Forme polymorphique de mesylate d'imatinib et ses procédés de préparation
WO2009151899A2 (fr) * 2008-05-26 2009-12-17 Dr. Reddy's Laboratories Ltd. Préparation de mésylate d’imatinib
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
TWI460472B (zh) * 2009-12-25 2014-11-11 Hon Hai Prec Ind Co Ltd 攜帶型電子裝置
WO2011095835A1 (fr) * 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Imatinib de grande pureté ou un sel pharmaceutiquement acceptable de celui-ci
WO2011099039A1 (fr) * 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Procédé pour la préparation d'une forme alpha de mésylate d'imatinib
PL390611A1 (pl) * 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2011158255A1 (fr) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Procédé pour la préparation de forme alpha de mésylate d'imatinib stable
EP2582689B1 (fr) * 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto Nouvelle forme polymorphique d'imatinib base et préparation de ses sels

Also Published As

Publication number Publication date
AU2014279765A1 (en) 2015-12-17
US20160122315A1 (en) 2016-05-05
WO2014199244A3 (fr) 2015-04-02
WO2014199244A2 (fr) 2014-12-18
CA2914669A1 (fr) 2014-12-18
EP3007699A2 (fr) 2016-04-20
EP3007699A4 (fr) 2017-01-18

Similar Documents

Publication Publication Date Title
US8269003B2 (en) Stable crystal form of imatinib mesylate and process for the preparation thereof
EP1720853B2 (fr) Compositions pharmaceutiques de la forme cristalline 2 du mésylate d'imatinib pour utilisation dans le traitement de la leucémie myéloïde chronique
TWI597277B (zh) 一種酪胺酸激酶抑制劑的二馬來酸鹽的第ｉ型結晶及製備方法
CN110650963B (zh) Gdc-0077的多晶型物和固体形式及其制备方法
US20140031352A1 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
WO2018117267A1 (fr) Sel de composé pipéridine substitué
CA2914669C (fr) Procede de preparation de mesylate d'imatinib cristallin
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
TW201638090A (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
EP2542548A1 (fr) Procédé pour la préparation de forme polymorphe et nouvelle forme polymorphe d'imatinib mésylate isolée dans ce procédé
JP7314319B2 (ja) Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途
TWI672302B (zh) Bcl-2抑制劑之新結晶型、其製備方法及含其之醫藥組合物
US9365559B2 (en) Crystal form of Dabrafenib and preparation method of use thereof
WO2016101868A1 (fr) Forme β-cristalline de tosylate de naputinib, procédé de préparation de ce composé et composition pharmaceutique contenant ce composé
AU2016318700A1 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
NZ630300A (en) Crystalline imatinib mesylate process
CN104788435A (zh) 一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐的i型结晶
CN106065016B (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
WO2024067085A1 (fr) Sel de citrate d'inhibiteur de kinase dépendante des cyclines (cdk4/6), forme cristalline de celui-ci, procédé de préparation correspondant et utilisation associée
JP2019505509A (ja) ゲフィチニブの結晶形ａを製造する方法
CN105461618A (zh) 甲磺酸洛美他派新晶型及其制备方法
WO2019029477A1 (fr) Forme cristalline de diméalate d'inhibiteur de tyrosine kinase et son procédé de préparation
CN106187905A (zh) 丁鲁他胺的结晶形式及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151207

MKLA Lapsed

Effective date: 20190404